Video

Dr. Hafron on PARP inhibitors in prostate cancer

“I think as our understanding of mutations [and] our understanding the PARP inhibitors [grows], if the data pans out, we'll be using these earlier and earlier in patients, which I think we'll [will allow us to] see probably more benefit,” says Jason M. Hafron, MD.

Video Player is loading.
Current Time 0:00
Duration 0:56
Loaded: 17.62%
Stream Type LIVE
Remaining Time 0:56
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected

    In a video interview conducted at the 2021 LUGPA annual meeting, Jason M. Hafron, MD, discussed how his practice is using PARP inhibitors for the treatment of prostate cancer. Hafron is a partner at the Michigan Institute of Urology, PC; an associate professor of urology at the William Beaumont School of Medicine, Oakland University; and the director of robotic surgery at Beaumont Hospital Royal Oak in Michigan.

    © 2025 MJH Life Sciences

    All rights reserved.